← All trials
NCT06329206
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2024
- Primary completion
- Apr 25, 2026
- Completion date
- Sep 1, 2026
- First posted
- Mar 25, 2024
- Last posted
- Jul 8, 2024
- Enrollment
- 156
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Genhouse Bio Co., Ltd.Lead sponsor
- Zhengzhou UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Wuhan UniversityCollaborator
- Henan Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.